Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions
MycosesCandidiasis, InvasiveCandidemia
Interventions
DRUG

SCY-078

DRUG

Fluconazole

DRUG

Micafungin

Trial Locations (30)

10467

Montefiore Medical Center, The Bronx

12208

Albany Medical Center, Albany

15213

University of Pittsburgh Medical Center, Pittsburgh

21205

Johns Hopkins University School of Medicine, Baltimore

27599

University of North Carolina, Chapel Hill

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

30912

Georgia Regents University, Augusta

33125

University of Miami, Miami

35233

University of Alabama at Birmingham, Birmingham

59701

Mercury Street Medical Group, Butte

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

75216

Dallas VA Medical Center, Dallas

75235

Parkland Hospital, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

77030

University of Texas Health Science Center at Houston, Houston

78229

South Texas Veterans Healthcare System, San Antonio

University of Texas Health Science Center at San Antonio, San Antonio

80045

University of Colorado Denver, Aurora

84112

University of Utah Hospitals and Clinics, Salt Lake City

95817

UC Davis Medical Center, Sacramento

02903

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

Unknown

Hospital Militar Central, San Salvador

Hospital Rosales, San Salvador

University of Cologne, Cologne

Hospital Mario Catarino Rivas, San Pedro Sula

Instituto Hondureno de Seguridad Social Sucursal San Pedro Sula, San Pedro Sula

Zona 16

Finca El Palomar, Guatemala City

All Listed Sponsors
lead

Scynexis, Inc.

INDUSTRY

NCT02244606 - Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis | Biotech Hunter | Biotech Hunter